Tuberculosis at extrapulmonary sites is relatively uncommon. A case of isolated involvement of the salivary gland is even rare and primary rifampicin mono-resistant tuberculosis of the parotid gland is rarest of rare with no such report ever documented in the medical literature. In this case report, the author presents a case of primary extrapulmonary rifampicin mono-resistant tuberculosis of the parotid gland in a 44-year-old Indian female. She presented with complaints of a painless swelling in the right parotid region and underwent a detailed diagnostic work-up including fine needle aspiration cytology, cartridge-based nucleic acid amplification test, computed tomography scan of head and neck, and culture, and was diagnosed with primary extrapulmonary rifampicin mono-resistant tuberculosis of the parotid gland. The patient was initiated on a WHO-recommended regimen per the national guidelines. After nine months of treatment, she had no symptoms and was declared as treatment completed. With no such case ever reported, this case emphasizes the importance of a high degree of suspicion for rare presentations of common diseases like tuberculosis even in the absence of a history, contacts, or other constitutional symptoms.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884326PMC
http://dx.doi.org/10.7759/cureus.33114DOI Listing

Publication Analysis

Top Keywords

rifampicin mono-resistant
16
mono-resistant tuberculosis
16
tuberculosis parotid
16
parotid gland
16
primary extrapulmonary
12
extrapulmonary rifampicin
12
indian female
8
tuberculosis
6
case
6
parotid
5

Similar Publications

Globally, drug-resistant tuberculosis (DR-TB) is responsible for 13% of mortality attributable to antimicrobial resistance. In Ethiopia, extrapulmonary tuberculosis (EPTB) is a significant public health challenge, and drug resistance (DR) in EPTB is often overlooked. In a cross-sectional study conducted between August 2022 and October 2023, we aimed to explore the magnitude of phenotypic drug resistance and identify genetic mutations linked to resistance using 189 Mycobacterium tuberculosis (MTB) isolates cultured from extrapulmonary clinical specimens.

View Article and Find Full Text PDF

Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.

J Clin Tuberc Other Mycobact Dis

December 2024

Médecins Sans Frontières, Southern Africa Medical Unit, Cape Town, South Africa.

Background: Tuberculosis (TB) remains a significant cause of mortality globally, with India accounting for 27% of the estimated number of people with TB. Multidrug-resistant TB (MDR-TB) and isoniazid (INH) resistance pose additional challenges to effective treatment. We aimed to describe treatment outcomes of INH mono-resistant TB patients under programmatic conditions in Mumbai, India.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the prevalence of mono-resistance to rifampicin and isoniazid in tuberculosis (TB) patients in Western Uttar Pradesh, finding that 19.51% were multi-drug resistant while 8.54% and 6.10% were mono-resistant to rifampicin and isoniazid, respectively.
  • - Out of 153 sputum samples processed, 54.24% tested positive for Mycobacterium tuberculosis, with the majority being identified through specific culture and testing methods.
  • - Findings indicate a higher occurrence of mono-resistance in male patients over 45, those living in rural areas, experiencing weight loss, or with previous TB treatment; the study calls for better monitoring
View Article and Find Full Text PDF
Article Synopsis
  • *A study conducted in Taiwan from 2008 to 2017 analyzed the treatment outcomes of patients with both drug-susceptible and isoniazid mono-resistant TB, finding no significant delays in sputum culture conversion or increased mortality for those with mono-resistance compared to drug-susceptible patients.
  • *However, younger, healthier patients without other health issues showed delayed culture conversion and worse outcomes, suggesting a need for early testing for isoniazid resistance in these groups to prevent potential disease spread.
View Article and Find Full Text PDF

Background And Objectives: Rifampicin (RIF) and isoniazid (INH), two most potent antibiotics, are prescribed to cure tuberculosis. , the causative agent of multidrug-resistant tuberculosis (MDR-TB), is resistant to these first-line drugs. Here, two molecular techniques were demonstrated such as PCR sequencing-based and GeneXpert assay for rapidly identifying MDR-TB.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!